Please assess the completion status of the following clinical trial:

Trial Title: A Study of Cytisinicline for Smoking Cessation in Adult Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects, age ≥18 years.~2. Current daily cigarette smokers (averaging at least 10 cigarettes per day upon completing a 7-day screening smoking diary) and who intend to quit smoking.~3. Expired air carbon monoxide (CO) ≥10 ppm.~4. Failed at least one previous attempt to stop smoking with or without therapeutic support.~5. Willing to initiate study treatment on the day after randomization and set a quit date within 5-7 days of starting treatment.~6. Willing to actively participate in the study's smoking cessation behavioral support provided throughout the study.~7. Able to fully understand study requirements, willing to participate, and comply with dosing schedule.~8. Sign the Informed Consent Form.~Exclusion Criteria:~1. More than 1 study participant in same household.~2. Previous cytisinicline treatment in a prior clinical study or any other cytisine usage.~3. Known hypersensitivity to cytisinicline or any of the excipients.~4. Positive urinary drugs of abuse screen, determined within 28 days before the first dose of cytisinicline.~5. Clinically significant abnormal serum chemistry or hematology values within 28 days of randomization (ie, requiring treatment or monitoring).~6. Clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined after minimum of 5 minutes in supine position within 28 days of randomization (ie, requiring treatment or further assessment).~7. Body mass index (BMI) classification for being underweight (\<18.5 kg/m\^2) or having ≥Class 2 obesity (≥35 kg/m\^2).~8. Recent history (within 3 months) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.~9. Current uncontrolled hypertension (blood pressure ≥160/100 mmHg).~10. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently psychotic.~11. Currently having suicidal ideation or risk for suicide (Yes to question 4 or question 5 OR Yes to any suicidal behavior question on the Columbia - Suicide Severity Rating Scale \[C-SSRS\]).~12. Current symptoms of moderate to severe depression (Hospital Anxiety and Depression Scale\[HADS\] score ≥11).~13. Renal impairment defined as a creatinine clearance (CrCl) \<60 mL/min (estimated with the Cockroft-Gault equation).~14. Hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.0 x the upper limit of normal (ULN).~15. Women who are pregnant or breast-feeding.~16. Male or female subjects of childbearing potential who do not agree to use acceptable methods of birth control during the study treatment period.~17. Participation in a clinical study with an investigational drug in the 4 weeks prior to randomization.~18. Treatment with other smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy \[NRT\]) in the 4 weeks prior to randomization or planned use of these other smoking cessation medications during the study.~19. Use within the 2 weeks prior to randomization or planned use during the study of non-cigarette and/or noncombustible nicotine products (pipe tobacco, cigars, snuff, smokeless tobacco, hookah, e-cigarettes/vaping) or marijuana smoking or vaping.~20. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + Behavioral Support (Type: PLACEBO_COMPARATOR): one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
- Cytisinicline + Placebo + Behavioral Support (Type: EXPERIMENTAL): one cytisinicline tablet PO TID plus behavioral support for 6 weeks followed by one placebo tablet PO TID plus behavioral support for 6 weeks
- Cytisinicline + Behavioral Support (Type: EXPERIMENTAL): one cytisinicline tablet PO TID plus behavioral support for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).